DTIL
Precision BioSciences, Inc.$7.01-0.04 (-0.64%)Prev Close$7.06·MCap$94.0M·P/E—·Vol45.9K·Yield—
▲
Buys (12M)
6
$63.2K
▼
Sells (12M)
11
$466.2K
◆
Net Activity
Net Seller
$403.0K
●
Active Insiders
7
last 12 mo
Over the past 12 months, insider activity at Precision BioSciences, Inc. (DTIL) has been dominated by selling, with 6 insider purchases totaling $63.2K and 11 insider sales totaling $466.2K. The most recent insider transaction was by Frankel Stanley (director), who purchased $6.0K worth of shares on Sep 30, 2026. Precision BioSciences, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $94.0M.
DTIL Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | Frankel Stanley | director | Buy | 1,000 | $6.00 | $6.0K | 41,478 |
| Sep 29, 2026 | Brown Melinda | director | Buy | 1,135 | $6.27 | $7.1K | 45,481 |
| Sep 29, 2026 | Germano Geno J | director | Buy | 2,609 | $6.28 | $16.4K | 47,492 |
| Feb 19, 2026 | Scimeca Dario | officer: General Counsel and Secretary | Sell | 4,925 | $3.84 | $18.9K | 56,457 |
| Feb 17, 2026 | Amoroso Michael | President and CEO | Sell | 20,559 | $3.84 | $78.9K | 0 |
| Feb 17, 2026 | Kelly John Alexander | Chief Financial Officer | Sell | 8,149 | $3.84 | $31.3K | 0 |
| Feb 17, 2026 | SMITH J. JEFFERSON | Chief Research Officer | Sell | 4,925 | $3.84 | $18.9K | 0 |
| Jan 22, 2026 | Amoroso Michael | director, officer: President and CEO | Sell | 34,799 | $4.17 | $145.1K | 196,154 |
| Jan 22, 2026 | Kelly John Alexander | officer: Chief Financial Officer | Sell | 15,213 | $4.03 | $61.3K | 106,448 |
| Jan 22, 2026 | Scimeca Dario | officer: General Counsel and Secretary | Sell | 8,854 | $4.03 | $35.7K | 44,715 |
| Jan 22, 2026 | SMITH J. JEFFERSON | officer: Chief Research Officer | Sell | 10,200 | $4.03 | $41.1K | 110,184 |
| Dec 17, 2025 | Brown Melinda | Director | Buy | 1,381 | $4.97 | $6.9K | 23,346 |
| Dec 17, 2025 | Frankel Stanley | Director | Buy | 2,700 | $4.70 | $12.7K | 19,478 |
| Dec 17, 2025 | Germano Geno J | Director | Buy | 3,000 | $4.72 | $14.2K | 23,883 |
| Nov 4, 2025 | Amoroso Michael | President and CEO | Sell | 3,409 | $6.49 | $22.1K | 115,575 |
| Nov 4, 2025 | Kelly John Alexander | Chief Financial Officer | Sell | 1,303 | $6.49 | $8.5K | 77,298 |
| Nov 4, 2025 | Scimeca Dario | General Counsel and Secretary | Sell | 665 | $6.49 | $4.3K | 28,258 |
| Sep 30, 2025 | Frankel Stanley | Director | Buy | 2,700 | $4.97 | $13.4K | 16,778 |
| Sep 24, 2025 | Brown Melinda | Director | Buy | 1,400 | $4.89 | $6.8K | 21,965 |
| Jul 8, 2025 | Kelly John Alexander | Chief Financial Officer | Sell | 14,827 | $4.26 | $63.2K | 73,485 |
| Jun 27, 2025 | Brown Melinda | Director | Buy | 1,682 | $4.14 | $7.0K | 20,565 |
| Jun 27, 2025 | Buehler Kevin | Director | Buy | 5,076 | $4.16 | $21.1K | 28,137 |
| Mar 28, 2025 | Brown Melinda | Buy | 1,839 | $4.75 | $8.7K | 9,057+25% | |
| Mar 28, 2025 | Buehler Kevin | Buy | 4,523 | $4.67 | $21.1K | 13,235+52% | |
| Mar 27, 2025 | Germano Geno J | Buy | 3,250 | $5.30 | $17.2K | 11,057+42% | |
| Mar 25, 2025 | Amoroso Michael | President and CEO | Sell | 964 | $5.56 | $5.4K | 109,540 |
| Mar 5, 2025 | Scimeca Dario | General Counsel and Secretary | Sell | 272 | $4.91 | $1.3K | 25,000 |
| Mar 5, 2025 | SMITH J. JEFFERSON | Chief Research Officer | Sell | 154 | $4.91 | $756.14 | 87,805 |
| Jan 22, 2025 | Amoroso Michael | President and CEO | Sell | 36,838 | $4.67 | $172.0K | 107,087-26% |
| Jan 22, 2025 | Scimeca Dario | General Counsel and Secretary | Sell | 8,928 | $4.79 | $42.8K | 24,353-27% |
| Jan 22, 2025 | SMITH J. JEFFERSON | Chief Research Officer | Sell | 10,287 | $4.79 | $49.3K | 87,440 |
| Jan 2, 2025 | Germano Geno J | Buy | 3,605 | $4.49 | $16.2K | 7,807+86% | |
| Dec 31, 2024 | Buehler Kevin | Buy | 4,320 | $4.88 | $21.1K | 8,712+98% | |
| Dec 31, 2024 | Kelly John Alexander | Chief Financial Officer | Buy | 2,113 | $4.75 | $10.0K | 40,186 |
| Dec 30, 2024 | Brown Melinda | Buy | 3,016 | $4.55 | $13.7K | 7,218+72% | |
| Nov 21, 2024 | Kelly John Alexander | Chief Financial Officer | Buy | 3,000 | $6.76 | $20.3K | 38,073 |
| Nov 5, 2024 | Amoroso Michael | President and CEO | Sell | 3,012 | $8.19 | $24.7K | 28,537 |
| Nov 5, 2024 | Scimeca Dario | General Counsel and Secretary | Sell | 588 | $8.19 | $4.8K | 7,969 |
| Jun 11, 2024 | Scimeca Dario | General Counsel and Secretary | Sell | 93 | $11.79 | $1.1K | 6,721 |
| Jun 11, 2024 | SMITH J. JEFFERSON | Chief Research Officer | Sell | 50 | $11.79 | $589.50 | 68,559 |
| May 3, 2024 | Amoroso Michael | President and CEO | Sell | 1,526 | $10.32 | $15.7K | 13,772 |
| May 3, 2024 | List Alan | Chief Medical Officer | Sell | 290 | $10.32 | $3.0K | 4,488 |
| May 3, 2024 | Scimeca Dario | General Counsel and Secretary | Sell | 272 | $10.32 | $2.8K | 5,680 |
| May 3, 2024 | SMITH J. JEFFERSON | Chief Research Officer | Sell | 154 | $10.32 | $1.6K | 67,613 |
| Apr 30, 2024 | List Alan | Chief Medical Officer | Sell | 238 | $10.03 | $2.4K | 3,796 |
| Jan 23, 2024 | Amoroso Michael | President and CEO | Sell | 137,390 | $0.36 | $49.5K1.1% OS | 356,433-28% |
| Jan 23, 2024 | List Alan | Chief Medical Officer | Sell | 21,526 | $0.36 | $7.7K | 94,982 |
| Jan 23, 2024 | Scimeca Dario | General Counsel and Secretary | Sell | 21,287 | $0.36 | $7.7K | 151,028 |
| Jan 23, 2024 | SMITH J. JEFFERSON | Chief Research Officer | Sell | 28,000 | $0.37 | $10.4K | 1,987,269 |
| Nov 6, 2023 | Amoroso Michael | President and CEO | Sell | 125,025 | $0.40 | $50.0K1.0% OS | 227,103-36% |
Showing 1–50 of 82
1 / 2
DTIL Insider Buying Activity
The following table shows recent insider purchases of Precision BioSciences, Inc. (DTIL) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | Frankel Stanley | director | Buy | 1,000 | $6.00 | $6.0K | 41,478 |
| Sep 29, 2026 | Brown Melinda | director | Buy | 1,135 | $6.27 | $7.1K | 45,481 |
| Sep 29, 2026 | Germano Geno J | director | Buy | 2,609 | $6.28 | $16.4K | 47,492 |
| Dec 17, 2025 | Brown Melinda | Director | Buy | 1,381 | $4.97 | $6.9K | 23,346 |
| Dec 17, 2025 | Frankel Stanley | Director | Buy | 2,700 | $4.70 | $12.7K | 19,478 |
| Dec 17, 2025 | Germano Geno J | Director | Buy | 3,000 | $4.72 | $14.2K | 23,883 |
| Sep 30, 2025 | Frankel Stanley | Director | Buy | 2,700 | $4.97 | $13.4K | 16,778 |
| Sep 24, 2025 | Brown Melinda | Director | Buy | 1,400 | $4.89 | $6.8K | 21,965 |
| Jun 27, 2025 | Brown Melinda | Director | Buy | 1,682 | $4.14 | $7.0K | 20,565 |
| Jun 27, 2025 | Buehler Kevin | Director | Buy | 5,076 | $4.16 | $21.1K | 28,137 |
| Mar 28, 2025 | Brown Melinda | Buy | 1,839 | $4.75 | $8.7K | 9,057+25% | |
| Mar 28, 2025 | Buehler Kevin | Buy | 4,523 | $4.67 | $21.1K | 13,235+52% | |
| Mar 27, 2025 | Germano Geno J | Buy | 3,250 | $5.30 | $17.2K | 11,057+42% | |
| Jan 2, 2025 | Germano Geno J | Buy | 3,605 | $4.49 | $16.2K | 7,807+86% | |
| Dec 31, 2024 | Buehler Kevin | Buy | 4,320 | $4.88 | $21.1K | 8,712+98% | |
| Dec 31, 2024 | Kelly John Alexander | Chief Financial Officer | Buy | 2,113 | $4.75 | $10.0K | 40,186 |
| Dec 30, 2024 | Brown Melinda | Buy | 3,016 | $4.55 | $13.7K | 7,218+72% | |
| Nov 21, 2024 | Kelly John Alexander | Chief Financial Officer | Buy | 3,000 | $6.76 | $20.3K | 38,073 |
DTIL Insider Selling Activity
The following table shows recent insider sales of Precision BioSciences, Inc. (DTIL) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 19, 2026 | Scimeca Dario | officer: General Counsel and Secretary | Sell | 4,925 | $3.84 | $18.9K | 56,457 |
| Feb 17, 2026 | Amoroso Michael | President and CEO | Sell | 20,559 | $3.84 | $78.9K | 0 |
| Feb 17, 2026 | Kelly John Alexander | Chief Financial Officer | Sell | 8,149 | $3.84 | $31.3K | 0 |
| Feb 17, 2026 | SMITH J. JEFFERSON | Chief Research Officer | Sell | 4,925 | $3.84 | $18.9K | 0 |
| Jan 22, 2026 | Amoroso Michael | director, officer: President and CEO | Sell | 34,799 | $4.17 | $145.1K | 196,154 |
| Jan 22, 2026 | Kelly John Alexander | officer: Chief Financial Officer | Sell | 15,213 | $4.03 | $61.3K | 106,448 |
| Jan 22, 2026 | Scimeca Dario | officer: General Counsel and Secretary | Sell | 8,854 | $4.03 | $35.7K | 44,715 |
| Jan 22, 2026 | SMITH J. JEFFERSON | officer: Chief Research Officer | Sell | 10,200 | $4.03 | $41.1K | 110,184 |
| Nov 4, 2025 | Amoroso Michael | President and CEO | Sell | 3,409 | $6.49 | $22.1K | 115,575 |
| Nov 4, 2025 | Kelly John Alexander | Chief Financial Officer | Sell | 1,303 | $6.49 | $8.5K | 77,298 |
| Nov 4, 2025 | Scimeca Dario | General Counsel and Secretary | Sell | 665 | $6.49 | $4.3K | 28,258 |
| Jul 8, 2025 | Kelly John Alexander | Chief Financial Officer | Sell | 14,827 | $4.26 | $63.2K | 73,485 |
| Mar 25, 2025 | Amoroso Michael | President and CEO | Sell | 964 | $5.56 | $5.4K | 109,540 |
| Mar 5, 2025 | Scimeca Dario | General Counsel and Secretary | Sell | 272 | $4.91 | $1.3K | 25,000 |
| Mar 5, 2025 | SMITH J. JEFFERSON | Chief Research Officer | Sell | 154 | $4.91 | $756.14 | 87,805 |
| Jan 22, 2025 | Amoroso Michael | President and CEO | Sell | 36,838 | $4.67 | $172.0K | 107,087-26% |
| Jan 22, 2025 | Scimeca Dario | General Counsel and Secretary | Sell | 8,928 | $4.79 | $42.8K | 24,353-27% |
| Jan 22, 2025 | SMITH J. JEFFERSON | Chief Research Officer | Sell | 10,287 | $4.79 | $49.3K | 87,440 |
| Nov 5, 2024 | Amoroso Michael | President and CEO | Sell | 3,012 | $8.19 | $24.7K | 28,537 |
| Nov 5, 2024 | Scimeca Dario | General Counsel and Secretary | Sell | 588 | $8.19 | $4.8K | 7,969 |
| Jun 11, 2024 | Scimeca Dario | General Counsel and Secretary | Sell | 93 | $11.79 | $1.1K | 6,721 |
| Jun 11, 2024 | SMITH J. JEFFERSON | Chief Research Officer | Sell | 50 | $11.79 | $589.50 | 68,559 |
| May 3, 2024 | Amoroso Michael | President and CEO | Sell | 1,526 | $10.32 | $15.7K | 13,772 |
| May 3, 2024 | List Alan | Chief Medical Officer | Sell | 290 | $10.32 | $3.0K | 4,488 |
| May 3, 2024 | Scimeca Dario | General Counsel and Secretary | Sell | 272 | $10.32 | $2.8K | 5,680 |
| May 3, 2024 | SMITH J. JEFFERSON | Chief Research Officer | Sell | 154 | $10.32 | $1.6K | 67,613 |
| Apr 30, 2024 | List Alan | Chief Medical Officer | Sell | 238 | $10.03 | $2.4K | 3,796 |
| Jan 23, 2024 | Amoroso Michael | President and CEO | Sell | 137,390 | $0.36 | $49.5K1.1% OS | 356,433-28% |
| Jan 23, 2024 | List Alan | Chief Medical Officer | Sell | 21,526 | $0.36 | $7.7K | 94,982 |
| Jan 23, 2024 | Scimeca Dario | General Counsel and Secretary | Sell | 21,287 | $0.36 | $7.7K | 151,028 |
| Jan 23, 2024 | SMITH J. JEFFERSON | Chief Research Officer | Sell | 28,000 | $0.37 | $10.4K | 1,987,269 |
| Nov 6, 2023 | Amoroso Michael | President and CEO | Sell | 125,025 | $0.40 | $50.0K1.0% OS | 227,103-36% |
DTIL Insiders
Kelly John Alexander
officer: Chief Financial Officer
Bought $209.3KSold $164.2K
10 tradesLast: Feb 17, 2026
Similar Stocks to DTIL
MRNA
Moderna, Inc.
$225.82+1.80%
$85.50B
REGN
Regeneron Pharmaceuticals, Inc.
$969.36+4.43%
$83.15B
RVMD
Revolution Medicines, Inc.
$190.88-0.20%
$39.42B
ALNY
Alnylam Pharmaceuticals, Inc.
$161.00-2.49%
$30.46B
UTHR
United Therapeutics Corporation
$595.67-0.51%
$25.15B
INCY
Incyte Corporation
$119.31-1.01%
$23.69B
INSM
Insmed Incorporated
$111.22-1.20%
$21.18B
EXEL
Exelixis, Inc.
$71.60+3.14%
$16.64B